Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort [2]

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 4, 2005, Pages 440-441

  Xie, Hong Guang ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; MULTIDRUG RESISTANCE PROTEIN 3; OMEPRAZOLE;

CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSPORT; GENOTYPE; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; LETTER; LONG TERM CARE; PHENOTYPE; PRIORITY JOURNAL;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ANTAGONISM; ENZYME INDUCTION; GENOTYPE; HUMANS; HYPERICUM; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; P-GLYCOPROTEIN; PLANT PREPARATIONS;

EID: 25844488118     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.07.009     Document Type: Letter

References (10)

1. L-S. Wang, G. Zhou, B. Zhu, J. Wu, J.G. Wang, A.M.A. El-Aty St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 2004 191 197
2. H. Yamazaki, K. Inoue, P.M. Shaw, W.J. Checovich, F.P. Guengerich, T. Shimada Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes effects of contents of these two forms in individual human samples J Pharmacol Exp Ther 283 1997 434 442
3. L-S. Wang, B. Zhu, A.M. El-Aty, G. Zhou, Z. Li, J. Wu The influence of St John's wort on CYP2C19 activity with respect to genotype J Clin Pharmacol 44 2004 577 581
4. J. Rengelshausen, M. Banfield, K-D. Riedel, J. Burhenne, J. Weiss, T. Thomsen Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics Clin Pharmacol Ther 78 2005 25 33
5. S. Krusekopf, I. Roots, U. Kleeberg Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43 Eur J Pharmacol 466 2003 7 12
6. H-G. Xie, R.B. Kim St John's wort-associated drug interactions short-term inhibition and long-term induction? Clin Pharmacol Ther 78 2005 19 24
7. J.W. Ko, N. Sukhova, D. Thacker, P. Chen, D.A. Flockhart Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms Drug Metab Dispos 25 1997 853 862
8. C. Pauli-Magnus, S. Rekersbrink, U. Klotz, M.F. Fromm Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein Naunyn Schmiedebergs Arch Pharmacol 364 2001 551 557
9. T. Takahata, N. Yasui-Furukori, G. Yoshiya, T. Uno, K. Sugawara, T. Tateishi Fexofenadine does not affect omeprazole pharmacokinetics both are putative P-glycoprotein substrates Basic Clin Pharmacol Toxicol 94 2004 252 256
10. M. Hitzl, K. Klein, U.M. Zanger, P. Fritz, A.K. Nussler, P. Neuhaus Influence of omeprazole on multidrug resistance protein 3 expression in human liver J Pharmacol Exp Ther 304 2003 524 530